|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM362994552 |
| 003 |
DE-627 |
| 005 |
20240509232245.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2024 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202308029
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1402.xml
|
| 035 |
|
|
|a (DE-627)NLM362994552
|
| 035 |
|
|
|a (NLM)37805865
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Wang, Ji
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Engineered mRNA Delivery Systems for Biomedical Applications
|
| 264 |
|
1 |
|c 2024
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 15.04.2024
|
| 500 |
|
|
|a Date Revised 08.05.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2024 Wiley‐VCH GmbH.
|
| 520 |
|
|
|a Messenger RNA (mRNA)-based therapeutic strategies have shown remarkable promise in preventing and treating a staggering range of diseases. Optimizing the structure and delivery system of engineered mRNA has greatly improved its stability, immunogenicity, and protein expression levels, which has led to a wider range of uses for mRNA therapeutics. Herein, a thorough analysis of the optimization strategies used in the structure of mRNA is first provided and delivery systems are described in great detail. Furthermore, the latest advancements in biomedical engineering for mRNA technology, including its applications in combatting infectious diseases, treating cancer, providing protein replacement therapy, conducting gene editing, and more, are summarized. Lastly, a perspective on forthcoming challenges and prospects concerning the advancement of mRNA therapeutics is offered. Despite these challenges, mRNA-based therapeutics remain promising, with the potential to revolutionize disease treatment and contribute to significant advancements in the biomedical field
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Review
|
| 650 |
|
4 |
|a biomaterials
|
| 650 |
|
4 |
|a delivery systems
|
| 650 |
|
4 |
|a mRNA
|
| 650 |
|
4 |
|a particles
|
| 650 |
|
4 |
|a therapeutics
|
| 650 |
|
7 |
|a RNA, Messenger
|2 NLM
|
| 700 |
1 |
|
|a Zhu, Haofang
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Gan, Jingjing
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Liang, Gaofeng
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Li, Ling
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhao, Yuanjin
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 36(2024), 15 vom: 05. Apr., Seite e2308029
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnns
|
| 773 |
1 |
8 |
|g volume:36
|g year:2024
|g number:15
|g day:05
|g month:04
|g pages:e2308029
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202308029
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 36
|j 2024
|e 15
|b 05
|c 04
|h e2308029
|